Takashi Miki tells HCPLive the effect didn't need immune iNKT cells, and suggests pairing GLP-1 drugs with PPARα activators for fatty liver disease.
Recap by typeshit. Full story at HCPLive.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
The tester liked the easy intake and fast shipping but wished he could have spoken with a provider before being approved.
Featured in Everyday Health, the NYITCOM doctor shares guidance on common mistakes people make with the new oral GLP-1 medications.
Loading…